Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A newly approved oral therapy is changing the game for TK2 deficiency (TK2D), a rare mitochondrial disease. Unlike supportive care, which only manages symptoms, doxecitine and doxribtimine target the root cause — and pooled data show treated patients live nearly twice as long and 75% regain lost motor milestones.
For patients with TK2 deficiency (TK2D), a rare mitochondrial disease, supportive care has long been the only option — improving quality of life but doing nothing to stop disease progression. Lost motor milestones stayed lost, and adults faced fatigue, muscle weakness, and a heavy socioeconomic toll. That's now changing.
The FDA approved doxecitine and doxribtimine in November 2025 for TK2D patients with onset at or before age 12. The oral therapy works by replenishing the depleted mitochondrial nucleotide pool — boosting substrate for residual TK2 activity and leveraging cytosolic kinase pathways to restore mitochondrial DNA levels and reduce oxidative phosphorylation impairment. In short, it targets the disease at its root.
By the Numbers:
Why it matters: This isn't just stabilization — it's genuine improvement. For a disease where regression was once the only trajectory, the ability to restore function and nearly double survival marks a meaningful shift in what's possible for TK2D patients and their families.
